SCHEMBL1202452

SCHEMBL1202452

O=C(O)c1ccc(NC(=O)c2cnc3ccc(OCc4ccc(Cl)c(Cl)c4)nn23)cc1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ FYN P06241 1/20 0.49
▸ MEN1 O00255 4/20 0.43
▸ KMT2A Q03164 4/20 0.43
▸ POLB P06746 1/20 0.43
▸ ALKBH1 Q13686 1/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ SMN1; SMN2 Q16637 3/20 0.41
▸ MAPK1 P28482 2/20 0.41
▸ IKBKB O14920 2/20 0.40
▸ CXCR2 P25025 1/20 0.40
▸ MRGPRX4 Q96LA9 1/20 0.40
▸ KDM5A P29375 1/20 0.39
▸ KDM4C Q9H3R0 1/20 0.39
▸ KDM5B Q9UGL1 1/20 0.39
▸ PTGDR2 Q9Y5Y4 3/20 0.39
▸ LMNA P02545 1/20 0.39
▸ TP53 P04637 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ TDP1 Q9NUW8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1202657 0.83 FYN (0.72) FYNIKBKB
SCHEMBL1203528 0.79 SGMS2 (0.47) MEN1KMT2ASMN1; SMN2CXCR2
SCHEMBL1203216 0.78 FYN (0.51) FYNMEN1KMT2APOLBKDM4E
SCHEMBL1202618 0.74 FYN (0.61) FYNIKBKB
SCHEMBL1202561 0.74 IKBKB (0.58) FYNMAPK1IKBKB
SCHEMBL1202981 0.74 MEN1 (0.40) MEN1KMT2APOLBKDM4ESMN1; SMN2
SCHEMBL1203079 0.72 KCNH2 (0.44) FYNKDM4EIKBKBCXCR2LMNA
SCHEMBL1202629 0.72 FYN (0.54) FYNMEN1KMT2APOLBKDM4E
SCHEMBL2906861 0.70 FYN (0.51) FYNIKBKB
SCHEMBL1202024 0.69 KIT (0.45) FYNIKBKBPTGDR2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110046127-A1 Imidazopyridazines for Use as Protein Kinase Inhibitors CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) 2011-02-24 — — US disclosed
EP-2217601-A1 IMIDAZOPYRIDAZINES FOR USE AS PROTEIN KINASE INHIBITORS Centro Nacional de Investigaciones Oncológicas (CNIO) (ES) 2010-08-18 — — EP disclosed
WO-2009060197-A1 IMIDAZOPYRIDAZINES FOR USE AS PROTEIN KINASE INHIBITORS CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) 2009-05-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046127-A1 Imidazopyridazines for Use as Protein Kinase Inhibitors PIM1, PIM3, PIM2 FYN 403/4885MEN1 2279/4885KMT2A 1247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback